Commercial Opportunities CHK1- and CHK2-SNPs have been well validated. Genotyping of these SNPs will allow identifying responders and non-responders under therapy with CHK-inhibitors and other anti-cancer drugs. Besides the pre-estimation of the efficacy of pharmacological therapies, dose adjustments of non-pharmacological therapies like irradiation should be possible. Genetic association studies have clearly demonstrated significant effects of CHK1- and CHK2-SNPs upon the outcome in different haematological and solid cancers. For example, excellent correlations with the progression of CLL, bladder, colorectal carcinoma and glioblastoma have been observed. The prognostic value will also be given for other cancer entities. Since the biological function of the CHK1 and CHK2 are well known and characterized, corresponding diagnostic tests will be widely accepted.
firstname.lastname@example.org | TechnologieAllianz e.V.
New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.
Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
15.12.2017 | Power and Electrical Engineering
15.12.2017 | Materials Sciences
15.12.2017 | Life Sciences